175 related articles for article (PubMed ID: 33388280)
21. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
22. Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts.
Bossé D; Xie W; Lin X; Simantov R; Lalani AA; Graham J; Wells JC; Donskov F; Rini B; Beuselinck B; Alva A; Hansen A; Wood L; Soulières D; Kollmannsberger C; Patenaude F; Heng DYC; Choueiri TK; McKay RR
JCO Glob Oncol; 2020 Feb; 6():293-306. PubMed ID: 32109159
[TBL] [Abstract][Full Text] [Related]
23. An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study.
Mosca A; De Giorgi U; Procopio G; Basso U; Cartenì G; Bersanelli M; Naglieri E; Galli L; Caffo O; Fornarini G; Boccardo F; Porta C
Jpn J Clin Oncol; 2021 Mar; 51(3):484-491. PubMed ID: 33212499
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
26. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
27. Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma.
Corona-Rodarte E; Olivas-Martínez A; Remolina-Bonilla YA; Domínguez-Cherit JG; Lam ET; Bourlon MT
Int J Dermatol; 2021 Oct; 60(10):1242-1247. PubMed ID: 33871070
[TBL] [Abstract][Full Text] [Related]
28. Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Chen X; Yao J; Liu L; Zheng W; Hu X; Zhu Y; Wang H; Guo J
Target Oncol; 2019 Apr; 14(2):187-195. PubMed ID: 30887420
[TBL] [Abstract][Full Text] [Related]
29. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma.
Jo H; Hong J; Kim H; Kim HR; Kwon GY; Kang KA; Park SY; Kim CK; Park BK; Chung JH; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH
Front Oncol; 2022; 12():874385. PubMed ID: 35574412
[TBL] [Abstract][Full Text] [Related]
30. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
31. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
32. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
34. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
35. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
36. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
37. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
[TBL] [Abstract][Full Text] [Related]
38. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer.
Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522
[TBL] [Abstract][Full Text] [Related]
39. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama B; Arranz Arija JA; Rodríguez Sánchez A; Pinto Marín A; Borrega García P; Castellano Gaunas DE; Rubio Romero G; Maximiano Alonso C; Villa Guzmán JC; Puertas Álvarez JL; Chirivella González I; Méndez Vidal MJ; Juan Fita MJ; León-Mateos L; Lázaro Quintela M; García Domínguez R; Jurado García JM; Vélez de Mendizábal E; Lambea Sorrosal JJ; García Carbonero I; González del Alba A; Suárez Rodríguez C; Jiménez Gallego P; Meana García JA; García Marrero RD; Gajate Borau P; Santander Lobera C; Molins Palau C; López Brea M; Fernández Parra EM; Reig Torras O; Basterretxea Badiola L; Vázquez Estévez S; González Larriba JL
Ann Oncol; 2016 Apr; 27(4):706-11. PubMed ID: 26658889
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]